It was found that the prognosis of patients with high expression of eIF4E was poor in BRCA, brain low-grade glioma, lung adenocarcinoma, cervical squamous cell carcinoma and adenocarcinoma, hepatocellular carcinoma and lung squamous cell carcinoma, while the low expression of eIF4E in renal clear cell carcinoma, hepatic clear cell carcinoma and colorectal cancer had poor prognosis (Fig. S1A-I). This evidence concerns the gene EIF4E and hepatocellular carcinoma.